Quarterly ResultMay 12, 2026, 04:03 PM
Verrica Q1 Revenue $5.0M; YCANTH Units Up 51.3% YoY to 15,302
AI Summary
Verrica Pharmaceuticals reported Q1 2026 total revenue of $5.0 million, including U.S. YCANTH net product revenue of $4.3 million, marking a 25.4% year-over-year increase. Demand for YCANTH, the only FDA-approved therapy for molluscum contagiosum, reached a record 15,302 dispensed applicator units, up 51.3% year-over-year, and has surpassed 100,000 units since launch. The company also announced the commercial launch of YCANTH in Japan and achieved over 50% of targeted enrollment in its Phase 3 common warts program, with a second trial expected to begin mid-2026. The net loss for the quarter was $9.7 million.
Key Highlights
- YCANTH dispensed applicator units grew to 15,302 in Q1 2026, up 51.3% year-over-year.
- Total revenue was $5.0 million in Q1 2026.
- U.S. YCANTH net product revenue was $4.3 million in Q1 2026, up 25.4% year-over-year.
- YCANTH has exceeded 100,000 total dispensed applicator units since launch.
- Over 50% of current targeted enrollment achieved in the first Phase 3 common warts trial.
- YCANTH commercially launched in Japan by partner Torii Pharmaceutical.
- Net loss for Q1 2026 was $9.7 million, or $0.45 per share.
- Research and development expenses increased to $3.9 million, primarily for common warts Phase 3.